{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:25:25Z","timestamp":1790663125156,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.leukres.2022.106962","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:43:21Z","timestamp":1663735401000},"page":"106962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population"],"prefix":"10.1016","volume":"123","author":[{"given":"Maria","family":"Bieniaszewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Sobieralski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Leszczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Dutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106962_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106962_bib2","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106962_bib3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2022.106962_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000366263","article-title":"Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2-negative myeloproliferative neoplasms","volume":"133","author":"Wojtaszewska","year":"2015","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2022.106962_bib6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Al Assaf","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2022.106962_bib8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106962_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106962_bib10","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2141.1997.3503164.x","article-title":"The effects of anagrelide on human megakaryocytopoiesis","volume":"99","author":"Solberg","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106962_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-0012.1996.tb00647.x","article-title":"Ketanserin: a new perspective in posttransplant erythrocytosis?","volume":"10","author":"Borawski","year":"1996","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.leukres.2022.106962_bib14","first-page":"2687","article-title":"Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study","volume":"9","author":"Cascavilla","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.leukres.2022.106962_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.12614","article-title":"Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2\/CALR\/MPL mutational status","volume":"96","author":"Mela Osorio","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106962_bib16","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.leukres.2022.106962_bib17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib19","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib20","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106962_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","article-title":"A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction","volume":"10","author":"Pancrazzi","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2022.106962_bib22","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib23","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.leukres.2012.11.004","article-title":"Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study","volume":"37","author":"Besses","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2022.106962_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40259-016-0170-9","article-title":"Anagrelide and mutational status in essential thrombocythemia","volume":"30","author":"Iurlo","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.leukres.2022.106962_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF02685904","article-title":"Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment","volume":"24","author":"Hultdin","year":"2007","journal-title":"Med. Oncol."},{"key":"10.1016\/j.leukres.2022.106962_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106962_bib28","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106962_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-017-0090-5","article-title":"Histomorphological responses after therapy with pegylated interferon \u03b1-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV","volume":"6","author":"Masarova","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2022.106962_bib30","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106962_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia Vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106962_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":"Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders","volume":"29","author":"Fruchtman","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2022.106962_bib33","first-page":"1306","article-title":"A long-term study of young patients with essential thrombocythemia treated with anagrelide","volume":"89","author":"Mazzucconi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2022.106962_bib34","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1002\/ajh.26114","article-title":"Young platelet millionaires with essential thrombocythemia","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106962_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146029","article-title":"Excess mortality in young patients with myeloproliferative neoplasms","volume":"138","author":"Abu-Zeinah","year":"2021","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:56Z","timestamp":1758934976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"alternative-id":["S0145212622001886"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106962","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106962"}}